Septerna, Inc.
Close on Oct 19, 2026
- Market cap
- $1.64B
- P/E (TTM)
- –
- Dividend yield
- –
About Septerna
Pharmaceutical Preparations, SIC 2834
Septerna, Inc. is a clinical-stage biotechnology company that discovers and develops oral small molecule drugs targeting G protein-coupled receptors. The company utilizes a proprietary platform to isolate, purify, and reconstitute receptor proteins outside cells to guide structure-based drug design and optimization. Its development pipeline includes experimental product candidates such as SEP-479 and SEP-631, which focus on endocrinology, immunology, inflammation, and metabolic conditions. Septerna also partners with pharmaceutical companies, including Novo Nordisk, to develop oral therapies for disorders such as obesity and type 2 diabetes. Its programs aim to serve patient populations affected by these diseases.
The company operates in the United States, maintaining leased office, research, and laboratory facilities. Its principal executive offices are located in South San Francisco, California.
Summary of the business section of Septerna's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Septerna, Inc.
- Headquarters
- South San Francisco, CA
- Address
- 250 East Grand Avenue, Suite 65 94080
- Phone
- (650) 338-3533
- Website
- septerna.com
- Employees
- 130, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Mateo, California
Stock & identifiers
- Ticker
- SEPN
- Exchange
- Nasdaq
- IPO date
- Oct 25, 2024
- Shares outstanding
- 47M, Aug 5, 2026
- Public float
- $363.30M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1984086
- CUSIP
- 81734D104
- ISIN
- US81734D1046
- EIN
- 84-3891440
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jeffrey Finer | Chief Executive Officer, Director | 826,907 |
| Rajiv Patni | Chief Medical Officer | – |
| Daniel D. Long | SVP, Drug Discovery | 96,412 |
| Elizabeth Bhatt | President and COO | 199,209 |
| Samira Shaikhly | Chief People Officer | 793 |
| Gil M. Labrucherie | Chief Financial Officer | 40,000 |
| Jae B. Kim | Chief Medical Officer | – |
| Uwe Klein | SVP, Biological Sciences | 119,912 |
| Mark Andrew Wilson | Chief Legal Officer | – |
| Ran Xiao | Interim CFO | 58,069 |
| Capital Healthcare Fund LP RA | Director | – |
| Rajeev M. Shah | Director | 725,443 |
| RA Capital Nexus Fund III, L.P. | Director | – |
| Peter Kolchinsky | Director | – |
| Ra Capital Management, L.P. | Director | – |
| Shalini Sharp | Director | – |
| Alan Ezekowitz | Director | 117,420 |
| Keith Michael Gottesdiener | Director | – |
| Bernard Coulie | Director | – |
| Jeffrey K. Tong | Director | – |
| Abraham Bassan | Director | – |
| Jake Simson | Director | – |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 130 full-time employees, 67 of whom have M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 25, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 22, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |